CFA
AIMT

Carroll Financial Associates’s Aimmune Therapeutics AIMT Stock Holding History

Carroll Financial Associates’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-910
Closed -$19K – 1763
2019
Q3 		$19K Hold
910
– – ﹤0.01% 851
2019
Q2 		$18K Sell
910
-645
-41% -$13.3K ﹤0.01% 865
2019
Q1 		$34K Buy
1,555
+405
+35% +$9.54K ﹤0.01% 635
2018
Q4 		$28K Buy
+1,150
New +$29.8K ﹤0.01% 600

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Carroll Financial Associates's AIMT Position: Q4 2019 in Review

Carroll Financial Associates sold out of Aimmune Therapeutics (AIMT) in Q4 2019, closing a stake of 910 shares — an estimated $19K sold.

Carroll Financial Associates first reported a position in AIMT in Q4 2018 and held it in 4 quarters. The position peaked at $34K in Q1 2019. 155 funds tracked by Wall St. Rank hold AIMT as of Q4 2019.

  • Carroll Financial Associates reported no remaining Aimmune Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Carroll Financial Associates sold 910 Aimmune Therapeutics shares in Q4 2019, an estimated $19K.
  • Carroll Financial Associates first reported a position in Aimmune Therapeutics in Q4 2018 and held it in 4 quarters.
  • Carroll Financial Associates's Aimmune Therapeutics position peaked at $34K in Q1 2019.
  • 155 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2019.

Based on Carroll Financial Associates's 13F filing for Q4 2019, filed 8 Jan 2020.